NeuroSense Therapeutics (NRSN) Institutional Ownership $1.03 -0.03 (-2.74%) As of 03:59 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for NeuroSense Therapeutics (NASDAQ:NRSN)CurrentInstitutional OwnershipPercentage1.04%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$2.17MNumber ofInstitutional Sellers(last 12 months)0 Get NRSN Insider Trade Alerts Want to know when executives and insiders are buying or selling NeuroSense Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data NRSN Institutional Buying and Selling by Quarter Remove Ads NeuroSense Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/17/2025Citadel Advisors LLC253,997$305K0.0%+640.9%1.858% 2/14/2025Jane Street Group LLC64,636$78K0.0%N/A0.473% 11/15/2024XTX Topco Ltd45,996$58K0.0%+40.9%0.336% 8/15/2024Armistice Capital LLC1,584,000$1.77M0.0%N/A11.591% 8/12/2024XTX Topco Ltd32,650$37K0.0%N/A0.239% 11/15/2023Armistice Capital LLC662,000$470K0.0%-47.7%6.051% 5/11/2023Meitav Investment House Ltd.95,000$193K0.0%N/A0.868% (Data available from 1/1/2016 forward)Remove Ads NRSN Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NRSN shares? During the previous two years, the following institutional investors and hedge funds held shares of NeuroSense Therapeutics shares: Armistice Capital LLC ($1.77M), Citadel Advisors LLC ($305K), Meitav Investment House Ltd. ($193K), and Jane Street Group LLC ($78K), XTX Topco Ltd ($58K).Learn more on NRSN's institutional investors. What percentage of NeuroSense Therapeutics stock is owned by institutional investors? 1.04% of NeuroSense Therapeutics stock is owned by institutional investors. Learn more on NRSN's institutional investor holdings. Which institutional investors have been buying NeuroSense Therapeutics stock? The following institutional investors have purchased NeuroSense Therapeutics stock in the last 24 months: Armistice Capital LLC ($1.58M), Citadel Advisors LLC ($219.72K), Meitav Investment House Ltd. ($95K), Jane Street Group LLC ($64.64K), and XTX Topco Ltd ($46.00K). How much institutional buying is happening at NeuroSense Therapeutics? Institutional investors have bought a total of 2,009,349 shares in the last 24 months. This purchase volume represents approximately $2.33M in transactions. Which NeuroSense Therapeutics major shareholders have been selling company stock? The following institutional investors have sold NeuroSense Therapeutics stock in the last 24 months: Armistice Capital LLC ($604K). How much institutional selling is happening at NeuroSense Therapeutics? Institutional investors have sold a total of 604,000 shares in the last 24 months. This volume of shares sold represents approximately $428.84K in transactions. Related Companies INCR Institutional Ownership AVTX Institutional Ownership ANRO Institutional Ownership RENB Institutional Ownership MGX Institutional Ownership IKNA Institutional Ownership PYXS Institutional Ownership KRON Institutional Ownership GANX Institutional Ownership ONCY Institutional Ownership This page (NASDAQ:NRSN) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NRSN Stock Free NRSN Stock Alerts